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A B S T R A C T   
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common heritable kidney 
disease. ADPKD leads to cysts, kidney enlargement and end-stage renal disease. ADPKD is mainly caused by 
variants in PKD1 and PKD2, with truncating PKD1 variants causing the most severe phenotype. This study aimed 
to characterize variants in Danish patients referred for screening of genes related to cystic kidney disease. 
Methods: 147 families were analysed for variants in PKD1, PKD2 and GANAB using next generation sequencing 
and multiplex ligation-dependent probe amplification. If a variant was identified, relatives were analysed for the 
specific variant using Sanger sequencing. 
Results: A pathogenic or possibly pathogenic variant was identified in 87% (103/118) of patients suspected to 
suffer from ADPKD, according to the requisition form. In total, 112 pathogenic or possibly pathogenic variants 
were observed, of which 94 were unique; 74 (79%) in PKD1 and 20 (21%) in PKD2, while 41 variants were novel. 
No variants in GANAB were observed. Ten recurrent variants were observed in 26 (26%) families. These were 
either PKD2 variants (N = 6) or non-truncating PKD1 variants (N = 4). Five of these were likely founder variants. 
Conclusions: The distribution of pathogenic or possibly pathogenic variants in the Danish ADPKD population is 
similar to that in other populations, except that recurrent truncating PKD1 variants appear to be rare, i.e. founder 
variants tend to be variant types associated with a mild phenotype. Patients with a mild phenotype may remain 
undiagnosed, consequently the frequency of founder variants and prevalence of ADPKD may be underestimated.   
1. Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common monogenic kidney disease (Torres and Harris, 2009). The 
disease leads to cyst formation and growth, massive kidney enlargement 
and, ultimately, end-stage renal disease (Rossetti et al., 2007). 
Most cases of ADPKD appear to be caused by heterozygosity for a 
pathogenic variant in PKD1 or PKD2: according to the literature, vari-
ants in PKD1 are identified in ~85% of ADPKD families with a known 
pathogenic variant, while variants in PKD2 are identified in ~15% of 
these families (Rossetti et al., 2007; Harris and Torres, 2014; Cornec-Le 
Gall et al., 2014; Paul and Vanden Heuvel, 2014). Within each of these 
genes, several thousands of unique variants are reported to be patho-
genic or likely pathogenic (Eggermann et al., 2006). Recently, hetero-
zygosity for variants in GANAB and DNAJB11 were reported to cause 
ADPKD in 0.3% and 0.1% of families, respectively (Porath et al., 2016; 
Cornec-Le Gall et al., 2018). Inter- and intra-familiar variability of the 
phenotype is observed for all types of variants, however, patients with 
truncating variants in PKD1 (large rearrangements, frameshifts, indels 
and variants affecting canonical splice sites) tend to have the most se-
vere phenotype (Hwang et al., 2016). 
Despite the large number of ADPKD patients undergoing genetic 
testing, it is often difficult to determine whether a variant in PKD1 or 
PKD2 is pathogenic, mostly because many variants are missense 
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variants, many are only identified in one family and some patients carry 
multiple variants (Carrera et al., 2016). Compiling findings in multiple 
studies of ADPKD families can be helpful in the classification of variants. 
In order to further characterize variants associated with ADPKD, we 
report the distribution of pathogenic or possibly pathogenic variants in 
Danish patients referred for screening of PKD1, PKD2, and GANAB 
during a five-year period. In addition, we report the observed novel 
variants associated with ADPKD and the occurrence of recurrent 
variants. 
2. Material and methods 
2.1. Patients 
This is a retrospective study including samples (N = 147) sent to the 
Department of Clinical Genetics, Aarhus University Hospital (AUH), 
Denmark, for screening of genes associated with cystic kidney disease 
from April 2014 to April 2019. This public laboratory was the first to 
offer the analysis in Denmark; therefore, most Danish patients analysed 
in this 5-year period were included in the present study. Screening was 
requested either from a department of clinical genetics or from a 
department of nephrology. 
Eighty-one patients (55%) were females. The median age at the time 
of laboratory analysis was 47 years (range: 0–76 years); 135 patients 
(92%) were 18 years or older at the time of analysis. 
Data including personal identifiers, the clinical indication for per-
forming the analysis as stated on the requisition form, type of tissue, 
method(s) and results were retrieved from the laboratory database of the 
Department of Clinical Genetics, AUH. In Denmark, quality control 
projects like the present, are exempted from approval by institutional 
review boards. As this study took place in a department of clinical ge-
netics, we did not have access to systematic and valid information about 
the phenotype, e.g. the severity of the disease. However, we did have 
access to pedigrees constructed at the departments of clinical genetics 
during the genetic work-up. 
We scrutinised the clinical information given on the requisition form. 
If it said that the patient was suspected of ADPKD or that the patient had 
cystic kidneys, we classified the patient as suspected to suffer from 
ADPKD. 118 patients fulfilled one of these criteria. For 27 patients there 
were clinical information on the requisition form, however neither 
ADPKD nor cystic kidneys were stated. For 2 patients no information 
regarding phenotype was given. 
3. Molecular analysis 
3.1. DNA extraction 
DNA had been extracted from peripheral blood, tissue sampes and 
amnion cells. 
3.2. Sequencing 
The genes PKD1 (NM_001009944.2), PKD2 (NM_000297.3) and 
GANAB (NM_198335.5) had been sequenced using a next generation 
sequencing (NGS) panel targeting exons. 1 μg DNA was used for con-
struction of a library for Illumina paired-end sequencing using the KAPA 
HTP Library Preparation Kit according to the manufacturer’s in-
structions (KAPA Biosystems Inc., Wilmington, MA, USA). The libraries 
were enriched for regions of interest using a customized targeting probe 
set (SeqCap EZ Choice, Roche Nimblegen, Inc., Madison, WI, USA) and 
sequenced on a MiSeq or NextSeq Sequencer (Illumina, San Diego, CA, 
USA). The sequencing reads were aligned to the human genome 
(GRCh37), and variants were called in coding exons and flanking re-
gions ± 10 bp, using Biomedical Genomics Workbench v.2 (CLC bio- 
Qiagen, Aarhus, Denmark). All regions not covered 30x were 
sequenced using direct Sanger sequencing; primer sequences and other 
PCR details are available upon request. 
Relatives had been analysed for the family-specific variant(s) by 
direct Sanger sequencing using BigDye® Terminator v1.1 Cycle 
Sequencing Kit, as described by the manufacturer (Applied Biosystems, 
Life Technology) and analysed using ABI 3500xl Genetic Analyzer 
(Applied Biosystems, CA, USA). Further details are available upon 
request. 
3.3. Multiplex ligation-dependent probe amplification assay 
All samples in which no pathogenic or possibly pathogenic variant 
(as defined below), was detected by sequencing, had been analysed for 
deletion/duplication of one or more exons by multiplex ligation- 
dependent probe amplification (MLPA) using probe sets P351 and 
P352 following the manufacturer’s instructions (MRC-Holland, 
Amsterdam, Holland). 
3.4. Variant filtration and classification 
Variants had been called in RefSeq for each gene, and the following 
variants had been excluded: synonymous variants except for those 
located ±2 bp of exon-intron borders; variants registered in a public 
database (ExAC, gnomAD, and/or whole-exome sequencing of 2000 
Danish individuals (Lohmueller et al., 2013)) with a minor allele fre-
quency (MAF) > 5% and variants detected in >10% of the patients 
registered in the in-house frequency database of the laboratory. 
In the present study, the variants, that had been reported by the 
clinical laboratory as clinically relevant were classified as follows: 
Variants were deemed to be known if listed in the Autosomal Dominant 
Polycystic Kidney Disease: Mutation Database (PKDB) (Eggermann 
et al., 2006) and/or published in the Human Genome Mutation Database 
(HGMD, Qiagen) (Stenson et al., 2003). Novel variants were classified 
using VarSome (Kopanos et al., 2019) exclusively. The software clas-
sifies variants according to the American College of Medical Genetics & 
Genomics (ACMG) guidelines (Richards et al., 2015) developed for 
interpretation of sequence variants. Known variants were further clas-
sified based on information in the PKDB. Both novel and known variants 
were classified into two groups: pathogenic (P) or possibly pathogenic 
(PP), (Table 1). Only variants classified as pathogenic and definitely 
pathogenic by ACMG and PKDB, respectively, were classified as P. 
Among the remaining variants those that were either classified as 
pathogenic, likely pathogenic or variant of uncertain significance by 
ACMG, and/or definitely pathogenic, highly likely pathogenic, likely 
pathogenic, likely hypomorphic or variant of uncertain significance by 
PKDB were classified as PP. Using this algorithm, the group of variants 
classified as PP is quite heterogenous. 
Segregation analysis was possible in 17 families with a PP variant; in 
two of these families, more than one informative meiosis was available. 
Included were only family members diagnosed with multiple bilateral 
kidney cysts and family members who were unaffected at the age of 40 
years or above. For phenotypic classification of family members, we 
used clinical data from the requisition forms and pedigrees drawn at 
departments of clinical genetics. 
Recurrent variants were accessed in the HGMD and the Danish Cystic 
Kidney Disease Registry developed by us, at the Department of Clinical 
Genetics, AUH, (Danish Data Protection Agency reference number: 1-16- 
02-364-13). This registry holds data on the phenotype and genotype of 
97 families in which a minimum of one family member suffers from a 
cystic kidney disease and has received counselling at the Department of 
Clinical Genetics, AUH, or Aalborg University Hospital, and/or had 
PKD1 and PKD2 analysed prior to April 2014. The analysis had been 
performed by commercial laboratories in Europe at the request of 
Department of Clinical Genetics, AUH. 
The description at protein level in all tables is given without any 
experimental evidence. 
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3.5. Statistics 
Differences in the distribution of variants in PKD2 and non- 
truncating variants in PKD1 (in-frame indels, alternative splicing and 
missense variants) in this study compared to other studies, were eval-
uated using Fisher’s exact test (p<0.05). 
4. Results 
During a five-year period, 147 patients were screened for pathogenic 
variants in PKD1, PKD2 and GANAB. Among 118 patients suspected to 
have ADPKD, a P or PP variant was identified in 103, producing a 
diagnostic yield of 87%. No P or PP variants were identified in the 29 
patients with cystic kidneys, for whom a specific suspicion of ADPKD 
was not indicated on the requisition form. 
In total, 112 P or PP variants were identified of which 94% (105/ 
112) were identified using NGS and 6% (7/112) using MLPA. A total of 
94 unique P or PP variants were observed: 74 in PKD1 and 20 in PKD2. 
No variants were observed in GANAB. The distribution of P and PP 
variants according to gene, is given in Table 2. For detailed information 
of P and PP variants, see Supplementary Table 1 and Supplementary 
Table 2. All variants can be found in PKDB. 
The majority of variants were missense (37%), followed by nonsense 
variants (27%), frameshift variants (18%), large rearrangements (7%), 
variants affecting canonical splice sites (6%), in-frame insertions/de-
letions of >5 amino acids (3%) and variants causing alternative splicing 
(1%), (Table 3). 
For the 103 patients in whom P or PP variants were identified, 
pedigrees were assessed. None of these patients appeared to be related. 
In 63 patients, one variant in PKD1 was identified, five patients had two 
variants in PKD1, 31 patients had one variant in PKD2, one patient had 
two variants in PKD2 and three patients had one variant in PKD1 and 
one variant in PKD2 (Supplementary Table 3). In five of the nine patients 
with two variants, one variant was classified as P and the other as PP. 
Both variants in the remaining four patients were classified as PP. For 
one variant, segregation analysis was informative: One patient carried 
two PP variants in PKD1: c.4562G > T and c.9829C > T. However, 
segregation analysis indicated that c.9829C > T alone is insufficient to 
cause ADPKD as it was identified in an unaffected relative. According to 
the PKDB, the variant c.9829C > T is classified as likely hypomorphic 
and might contribute to disease when observed in combination with 
other variants. 
Ten recurrent variants were observed in a minimum of 2 and up to 7 
families. A total of 27 families harboured a recurrent variant. In one of 
these families, two recurrent variants were observed. Recurrent variants 
were identified both in PKD1 (N = 4) and PKD2 (N = 6). Eight of these 
variants were known, and two were novel, (Table 4). In the family 
harbouring two recurrent variants, one of these was c.8293C > T in 
PKD1. The frequency of this variant in the background population is 
0.8565% according to GnomAD, and the variant is classified as benign 
according to VarSome and as likely hypomorphic according to the PKDB 
and the literature (Rossetti et al., 2009). 
5. Discussion 
This study included 147 patients, of whom 118 were specifically 
suspected to suffer from ADPKD according to information given by the 
doctor requesting the gene analysis. A pathogenic or possibly pathogenic 
variant was identified in 103 of these 118 patients, whereas no such 
variants were observed among 29 patients for whom analysis of PKD1, 
PKD2, and GANAB was requested without the requisition form indi-
cating a suspicion of ADPKD. Hence, the diagnostic yield was 70% (103/ 
147) among all patients, and 87% (103/118) among patients specifically 
indicated to be suspected of ADPKD. The diagnostic yield was 80% in an 
Italian cohort in which 21.8% of the patients had an uncertain clinical 
diagnosis (Carrera et al., 2016). Yields in other studies of Caucasians 
range from 89.1 to 92.4% (Rossetti et al., 2007; Hwang et al., 2016; 
Audrezet et al., 2012; Heyer et al., 2016). Barring one (Hwang et al., 
2016), these studies included patients diagnosed using Pei’s criteria 
(Ravine et al., 1994). The yield observed in the present study is rela-
tively high taking into account that in Denmark patients with a classic 
ADPKD phenotype and a family history are mainly diagnosed using Pei’s 
criteria, only, unless prenatal diagnostics or predictive testing is 
requested (Autosomal dominant polycy, 2012), which should cause an 
increase in the fraction of patients with a mild or otherwise unusual 
phenotype among those analysed. Consistently, a non-significant (p =
0.7215 and p = 0.1452, respectively) but higher frequency of PKD2 
(21%) and non-truncating PKD1 variants (36%) was identified among 
the Danish patients (Table 3) than in similar studies from other countries 
(Rossetti et al., 2007; Hwang et al., 2016; Audrezet et al., 2012; Heyer 
et al., 2016), in which the averages were 18% and 27%, respectively. 
Identifying the cause of ADPKD is hampered by the fact that many 
cases are caused by missense variants that are difficult to classify beyond 
variant of uncertain significance (VUS). Furthermore, since most of 
these variants are unique to one family, it is difficult to obtain infor-
mation that indicates association. As observed in Supplementary 
Table 2, several variants have been classified differently using VarSome 
and PKDB. While currently it is not known which classification method 
most correctly classifies ADPKD variants, aggregated data from multiple 
studies should improve variant classification. Furthermore, our classi-
fication system is strong with regard to reproducibility in that we used 
Table 1 
Classification of variants.  
PKDB   ACMG   
Pathogenic Likely pathogenic Variant of uncertain significance Likely benign Benign 






























Highly likely pathogenic 
Likely pathogenic 
Likely hypomorphic 
Variant of uncertain significance 
Not available  
a P: Pathogenic. 
b Combination not observed. 
c PP: Possibly pathogenic. 
Table 2 
Distribution of known and novel variants in PKD1 and PKD2, by classification.  






Total distribution of 
variants (N = 94) 
PKD1 Pathogenic 53% (20/38) 47% (18/38) 40% (38/94)  
Possibly 
pathogenic 
53% (19/36) 47% (17/36) 38% (36/94) 
PKD2 Pathogenic 62% (8/13) % (5/13) 14% (13/94)  
Possibly 
pathogenic 
86% (6/7) 14% (1/7) 7% (7/94)  
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standard software (VarSome), rather than inventing our own scoring 
system. 
In the present study, identical variants were detected in several 
families. Due to the unique civil registration number assigned to all 
people living in Denmark, we could ensure that these families were not 
closely related. Furthermore, some of the families had been subjected to 
genetic work-up including drawing of pedigrees. In total, 26% of the 
families had a recurrent variant (Table 4), which is similar to the 
20–30% reported in other studies in Caucasians (Rossetti et al., 2007; 
Audrezet et al., 2012). 
To explore the recurrence of these variants in the Danish population, 
we examined if they were included in The Danish Cystic Kidney Disease 
Registry. Four of ten variants observed in two or more families in the 
present study were registered in 1–4 families in the registry. We found 
none of the variants described as recurrent in the literature, see Table 4. 
Recurrent variants may be founder variants or identical variants that 
have arisen independently. The latter are often indels generated by non- 
homologous recombination or single nucleotide substitutions in CpG 
dinucleotides (i.e., transitions of C to T or G to A). Indels are frequently 
generated when recombination occurs between two similar but non- 
identical sites (Chen et al., 2010). One variant in PKD2 (c.(2392_2664) 
_(2861_?)del) was likely generated by non-homologous recombination, 
and four variants were located at CpG sites: c.6643C > T and c.8293C >
T in PKD1, and c.1521C > T and c.2614C > T in PKD2. These variants 
were observed in three, two, three, two and five unrelated families, 
respectively, (Table 4). These five variants may have arisen indepen-
dently in each family, although it cannot be excluded that some of them 
might be founder variants, especially the PKD2 variant observed in five 
unrelated families. 
Five variants that were neither indels nor located at CpG sites 
remained: two nontruncating variants located in PKD1 were each 
observed in two families, and three located in PKD2 were observed in 
six, eight and nine families, respectively. The mutation rate in PKD1 and 
PKD2 is thought to be similar to the mutation rate in other large genes 
associated with autosomal dominant disorders (Rossetti et al., 2001). 
Although no definite conclusions have been reached regarding how to 
Table 3 
Distribution of pathogenic and possibly pathogenic variants in PKD1 and PKD2, by variant type.   
PKD1  PKD2  Total 
Type of variant Pathogenic (N =
38) 










(N = 94) 
Large rearrangementa 7% (5/74) 1% (1/74) 8% (6/74) 5% (1/20) 0% (0/20) 5% (1/20) 7% (7/94) 
Nonsense 27% (20/74) 1% (1/74) 28% (21/ 
74) 
20% (4/20) 0% (0/20) 20% (4/20) 27% (25/ 
94) 
Frame shift 15% (11/74) 3% (2/74) 18% (13/ 
74) 
20% (4/20) 0% (0/20) 20% (4/20) 18% (17/ 
94) 
Canonical splice site 3% (2/74) 0% (0/74) 3% (2/74) 20% (4/20) 0% (0/20) 20% (4/20) 6% (6/94) 
In-frame indel >5 amino 
acidsb 
0% (0/74) 4% (3/74) 4% (3/74) 0% (0/20) 0% (0/20) 0% (0/20) 3% (3/94) 
Atypical splicing 0% (0/74) 1% (1/74) 1% (1/74) 0% (0/20) 0% (0/20) 0% (0/20) 1% (1/94) 
Missense 0% (0/74) 38% (28/74) 38% (28/ 
74) 
0% (0/20) 35% (7/20) 35% (7/20) 37% (35/ 
94)  
a Large rearrangements: deletion or duplication of one or more exons detected by multiplex ligation-dependent probe amplification. 
b Indels: Insertions or deletions. 
Table 4 
Recurrent variants in PKD1 and PKD2.   
Genea 













PKD1 c.6643C > T p. 
Arg2215Trp 
2 + 0 = 2 0 LP 0.001893 Y Cornec-Le Gall (2013) J Am Soc Nephrol 24: 
1006; Kim (2019) Sci Rep 9: 16,952 
PKD1 c.7115C > G p. 
Ser2372Cys 
2 + 0 = 2 1 LP 0 N Audrézet (2012) Hum Mutat 33, 1239: 
Cornec-Le Gall (2013) J Am Soc Nephrol 
24: 1006  
PKD1 c.8293C > T p. 
Arg2765Cys 
2c+1 = 3 0 LH 0.8565 Y Rossetti et al. (2009) Kidney Int 75, 848; 
Gonzalez-Paredes (2014) Gene 546: 243 
PKD1 c.11249G > A p. 
Arg3750Glu 
2 + 0 = 2 NA HLP 0 N Hoefele (2010) Nephrol Dial Transplant 26, 
2181; Cornec-Le Gall (2013) J Am Soc Nephrol 
24: 1006; Carrera et al. (2016) Sci Rep 6: 30, 
850 
PKD2 c.1521G > A p.Trp 507* 2 + 0 = 2 0 NA 0 Y Robinson (2012) BMC Nephrol 13, 79 
PKD2 c.(2392_2664)_ 
(2861_?)del 
p.? 2 + 1 = 3 0 NA NA N NA 
PKD2 c.2119-2 A > G p.? 2 + 4 = 6 0 NA 0 N NA 
PKD2 c.2241-2 A > G p.? 7c+2 = 9 1 DP 0 N Veldhuisen (1997) Am J Hum Genet 61, 547 
PKD2 c.2600 T > C p.Leu867Pro 4 + 4 = 8 5 NA 0 N Robinson (2012) BMC Nephrol 13, 79 
PKD2 c.2614C > T p.Arg 872* 3 + 2 = 5 1 DP 0.0008818 Y Neumann (2013) Nephrol Dial Transplant 28, 
1472  
a PKD1 (NM_001009944.2) and PKD2 (NM_000297.3). 
b Number of families in the dataset + number of families in the Danish Cystic Kidney Disease Registry. 
c One family harbours both variants. 
d Number of meioses in which the variant co-segregated with the phenotype for all families harbouring the variant. 
e LP; Likely pathogenic; LH: Likely hypomorphic; HLP: Highly likely pathogenic; NA: Not available; DP: Definitely pathogenic. 
f NA: Not available. gVariant located at CpG site; Y: Yes; N: No. 
g NA: Not available. gVariant located at CpG site; Y: Yes; N: No. 
h NA: Not available. gVariant located at CpG site; Y: Yes; N: No. 
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predict mutational hotspots, mutations are more frequent in CpG sites 
and where similar sites increase the risk of non-homologous recombi-
nation. Hence, it appears unlikely that the same variants not related to 
non-homologous recombination or located within CpG sites have arisen 
independently in up to nine families. Thus, at least some of these vari-
ants most likely originated in a common ancestor, i.e. being founder 
variants. 
Similarly, the majority of variants found in more than one family in 
an Italian cohort (Carrera et al., 2016) and the TGESP cohort (Hwang 
et al., 2016) were PKD2 or non-truncating PKD1 variants. Like our study, 
these studies also did not recruit patients solely diagnosed by ultrasonic 
criteria. Truncating PKD1 variants are associated with a more severe 
phenotype than variants in PKD2 and non-truncating PKD1 variants 
(Hwang et al., 2016). Patients with truncating PKD1 variants may 
therefore have reduced survival and reproductive fitness (Rossetti et al., 
2001), which may cause recurrent truncating PKD1 variants to be un-
derrepresented. Therefore, variants associated with a mild phenotype 
are more likely to be transmitted through multiple generations, resulting 
in a high number of seemingly unrelated families harbouring the same 
variant. In the CRISP (Rossetti et al., 2007) and Genkyst cohorts 
(Audrezet et al., 2012), the majority of recurrent variants were trun-
cating PKD1 variants. However, in these cohorts, patients are diagnosed 
solely by Pei’s criteria, decreasing the probability that patients with a 
mild phenotype are included. This implies that both the frequency of 
recurrent variants associated with a mild phenotype and the number of 
families harbouring such variants may be higher than previously re-
ported. Supporting this, the prevalence of ADPKD reported in many 
studies is lower than the theoretical prevalence reported by Dalgaard 
(1957) and others (Solazzo et al., 2018). 
Conclusion: A pathogenic or possibly pathogenic variant was iden-
tified in 87% of the Danish families expected to suffer from ADPKD; 79% 
and 21% of the variants were identified in PKD1 and PKD2, respectively. 
94/112 variants were observed once, and 41 of these were novel. Ten 
variants in PKD2 or non-truncating variants in PKD1 were observed in 
multiple families. These types of variants often cause a mild phenotype 
compared to truncating PKD1 variants. Among the recurrent variants, at 
least five were most likely founder variants. Founder variants causing a 
mild phenotype may be more common than previously reported, and the 
prevalence of ADPKD may be underestimated. 
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